SCHEMBL7091629

SCHEMBL7091629

CC(=O)Nc1ccc(-c2ccccc2C(=O)C[N+](=O)[O-])c(Cl)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP19A1 P11511 1/20 0.36
PDE7A Q13946 1/20 0.36
POLB P06746 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
PARP14 Q460N5 1/20 0.34
MAPT P10636 2/20 0.34
MAOA P21397 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7088791 0.92 KMT2A (0.37) CYP2C19ALDH1A1CYP3A4CYP2D6KDM4E
SCHEMBL7088769 0.87 CYP2C19 (0.34) CYP2C19ALDH1A1CYP3A4CYP2D6KDM4E
SCHEMBL7085464 0.82 CYP2C19 (0.41) CYP2C19ALDH1A1CYP3A4CYP2D6KDM4E
SCHEMBL7090489 0.80 RORC (0.47) CYP2C19ALDH1A1CYP3A4CYP2D6NPC1
SCHEMBL8208914 0.80 KMT2A (0.39) ALDH1A1KDM4EHSD17B10CYP19A1PDE7A
SCHEMBL8752479 0.79 CYP2C19 (0.53) CYP2C19ALDH1A1CYP3A4CYP2D6KDM4E
SCHEMBL9640825 0.78 KDM4E (0.61) CYP2C19ALDH1A1CYP3A4CYP2D6KDM4E
SCHEMBL9641124 0.73 KMT2A (0.43) ALDH1A1KDM4EHSD17B10CYP19A1POLB
SCHEMBL8480172 0.72 KMT2A (0.48) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL9639607 0.72 KDM4E (0.49) ALDH1A1KDM4EHSD17B10PDE7APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US claimed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US claimed
US-5932765-A REDUCTASE INHIBITORS MERCK PATENT GESELLSCHAFT MIT (DE) 1999-08-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 CYP2C19 976/4885ALDH1A1 33/4885CYP3A4 300/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 CYP2C19 612/4885ALDH1A1 63/4885CYP3A4 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.